OPKO Health to Report Second Quarter 2021 Financial Results on July 29, 2021

Jul 20, 2021

OPKO Health Licenses Oligonucleotide Therapeutics Platform to CAMP4 Therapeutics

Jul 12, 2021

OPKO Health to Present at the Ladenburg Thalmann Healthcare Conference

Jul 8, 2021

OPKO Health Appoints Katherine Stueland as President and CEO of GeneDx

Jun 22, 2021

BioReference Laboratories Announces First COVID-19 Testing Program for Cruise Industry

Jun 22, 2021

OPKO Health to Develop and Commercialize RAYALDEE® in Greater China with Nicoya Therapeutics

Jun 21, 2021

OPKO Health Announces Sale of its Sterile Fill and Finish Manufacturing Facility in Ireland

Jun 17, 2021

OPKO Health to Participate in the Jefferies Virtual Healthcare Conference

May 27, 2021

OPKO Health Reports Transfer of Licensed Rights to RAYALDEE® in Japan to Vifor

May 24, 2021

OPKO Health Enters into Exchange Agreements with Certain 4.5% Convertible Senior Noteholders

May 7, 2021